D3 Bio
Temasek-backed D3 Bio secures $108M in Series B financing to advance global clinical programs
D3 Bio, a global clinical-stage biotechnology company focused on the discovery and development of innovative oncology therapeutics, has announced the completion of a $108 million Series B financing round.
